EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer

Lu Xia iD, Jichuan Wang, Hui Xue, Haimeng Li, Qinghua Li, Sen Qin, Chunyu Yu, Yanhua Liu, Yu Gao, Lingyun Li, Sudun Guan, Enrun Zheng und 7 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202410945 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Lu Xia und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Labor…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of China, National Natural Science Foundation of China, Natural Science Foundation of Beijing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aberrant EGFR signaling drives non‐small cell lung cancer (NSCLC) development, and despite the success of tyrosine kinase inhibitor (TKI) therapies in treating NSCLC, TKI resistance remains a major obstacle. Here, we report that the chemokine‐like transmembrane protein CMTM6 is physically associated with EGFR. CMTM6 is shown to be co‐localized with EGFR in recycling endosomes that are marked by RAB11, thereby preventing EGFR from lysosome‐mediated degradation in NSCLC cells. The level of CMTM6 is elevated in NSCLC, and high expression of CMTM6 is associated with enhanced colocalization of CMTM6 with EGFR and RAB11 in NSCLC tumors and correlated with a poor prognosis in NSCLC patients. A CMTM6‐targeting nanobody is developed and administration of this agent leads to blocking of the CMTM6‐EGFR interaction, reduction of the EGFR protein level, and inhibition of the proliferation of TKI‐resistant NSCLC cells in vitro and suppression of the growth of EGFR‐TKI‐resistant NSCLC in both cell line‐derived xenografts and patient‐derived xenograft models. The study indicates that CMTM6 is a stabilizer of EGFR in endocytic trafficking and provides evidence to support targeting CMTM6 as a potential therapeutic strategy to overcome TKI resistance in NSCLC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmProtein Kinase InhibitorsSingle-Domain AntibodiesChemokinesMARVEL Domain-Containing ProteinsMyelin ProteinsHumansErbB ReceptorsAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysFemale

Stichwörter der Autor:innen

CMTM6EGFREGFR‐TKIs resistanceNSCLCnanobody

Substanzen

ErbB ReceptorsCMTM6 protein, humanProtein Kinase InhibitorsEGFR protein, humanSingle-Domain AntibodiesChemokinesMARVEL Domain-Containing ProteinsMyelin Proteins

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Peking University International Cancer Institute, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Scienc…
  • Musculoskeletal Tumor Center, Beijing Key Laboratory for Musculoskeletal Tumors, Peking University People's Hospital, Beijing, 100044, China.
  • Department of Immunology, School of Basic Medical Sciences, Peking University Health Science Center, NHC Key Laboratory of Medical Immunology, Peking University Center for Human Disease Genomics, Beijing, 100191, China.
  • Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou, 311121, China.
  • Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, State Key Laboratory of Molecular Oncology, Peking University Health Science Center, Beijing, 100191, China.
  • Thoracic Oncology Ward, West China Hospital Cancer Center, Sichuan University, Chengdu, 610041, China.

ORCID-Profile: Lu Xia, Yongfeng Shang, Luyang Sun

Förderung

  • Ministry of Science and Technology of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Beijing
  • National Key Research and Development Program of China
  • Science and Technology Commission of Shanghai Municipality
  • Peking University
  • Beijing Physician Scientist Training Project
  • Ministry of Science and Technology of the People's Republic of China

Zitieren

APA

Xia, L., Wang, J., Xue, H., Li, H., Li, Q., Qin, S., Yu, C., Liu, Y., Gao, Y., Li, L., Guan, S., Zheng, E., Suo, F., He, L., Wang, Y., Han, W., Shang, Y., Geng, Y., & Sun, L. (2025). A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer. Advanced Science. https://doi.org/10.1002/advs.202410945

Vancouver

Xia L, Wang J, Xue H, Li H, Li Q, Qin S, et al. A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer. Advanced Science. 2025. doi:10.1002/advs.202410945

BibTeX
@article{Xia2025,
  author = {Xia, Lu and Wang, Jichuan and Xue, Hui and Li, Haimeng and Li, Qinghua and Qin, Sen and Yu, Chunyu and Liu, Yanhua and Gao, Yu and Li, Lingyun and Guan, Sudun and Zheng, Enrun and Suo, Feiya and He, Lin and Wang, Yongsheng and Han, Wenling and Shang, Yongfeng and Geng, Yong and Sun, Luyang},
  title = {A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202410945}
}
Kostenlos starten →